117 related articles for article (PubMed ID: 7850029)
1. Inhibition of the classical and alternative pathways of the human complement system by glycosaminoglycan polysulfate.
de Messias IT; Mohren D; Kajdacsy-Balla A
J Investig Allergol Clin Immunol; 1994; 4(4):172-6. PubMed ID: 7850029
[TBL] [Abstract][Full Text] [Related]
2. Comparative study of in vitro inhibition of activation of the classical and alternative pathways of human complement by the magnesium and sodium salts of the anti-inflammatory peptide N-acetyl-aspartyl-glutamic acid (NAAGA).
Feuillard J; Maillet F; Goldschmidt P; Weiss L; Kazatchkine MD
Agents Actions; 1991 Mar; 32(3-4):343-6. PubMed ID: 1862751
[TBL] [Abstract][Full Text] [Related]
3. In vitro inhibition of the classical pathway of human complement by a natural microbial product, colistin sulphate.
Asghar SS; de Koster A; van der Helm HJ
Biochem Pharmacol; 1986 Sep; 35(17):2917-21. PubMed ID: 3638137
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of equine complement activity by polysulfated glycosaminoglycans.
Rashmir-Raven AM; Coyne CP; Fenwick BW; Gaughan EM; Andrews GA; DeBowes RM
Am J Vet Res; 1992 Jan; 53(1):87-90. PubMed ID: 1539920
[TBL] [Abstract][Full Text] [Related]
5. Multiple effects of a diamidine (propamidine) on complement activation.
Vogt W; Hinsch B; Schmidt G; Von Zabern I
Immunology; 1979 Jan; 36(1):131-7. PubMed ID: 422224
[TBL] [Abstract][Full Text] [Related]
6. In vitro inhibition of the classical and alternate pathways of activation of human complement by N acetyl aspartyl glutamic acid (NAAGA).
Etievant M; Leluc B; David B
Agents Actions; 1988 Jun; 24(1-2):137-44. PubMed ID: 3261498
[TBL] [Abstract][Full Text] [Related]
7. Serglycin inhibits the classical and lectin pathways of complement via its glycosaminoglycan chains: implications for multiple myeloma.
Skliris A; Happonen KE; Terpos E; Labropoulou V; Børset M; Heinegård D; Blom AM; Theocharis AD
Eur J Immunol; 2011 Feb; 41(2):437-49. PubMed ID: 21268013
[TBL] [Abstract][Full Text] [Related]
8. The inhibitory effect of rosmarinic acid on complement involves the C5 convertase.
Peake PW; Pussell BA; Martyn P; Timmermans V; Charlesworth JA
Int J Immunopharmacol; 1991; 13(7):853-7. PubMed ID: 1761351
[TBL] [Abstract][Full Text] [Related]
9. Equine alternative pathway activation by unsensitized rabbit red blood cells.
Leid RW; Coley SC; Blanchard DP; Perryman LE
Vet Immunol Immunopathol; 1985 May; 9(1):71-85. PubMed ID: 4024451
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the classical and alternative pathways of human and guinea pig complement by pyran copolymer.
Webster GF; McArthur WP
Int Arch Allergy Appl Immunol; 1981; 66(3):304-9. PubMed ID: 6913544
[TBL] [Abstract][Full Text] [Related]
11. [Modification of proteolytic complement cascade after treatment with exogenous heparin].
Galebskaia LV; Solovtsova IL; Riumina EV
Vopr Med Khim; 2001; 47(1):91-7. PubMed ID: 11386002
[TBL] [Abstract][Full Text] [Related]
12. Effect of supraphysiologic levels of C1-inhibitor on the classical, lectin and alternative pathways of complement.
Nielsen EW; Waage C; Fure H; Brekke OL; Sfyroera G; Lambris JD; Mollnes TE
Mol Immunol; 2007 Mar; 44(8):1819-26. PubMed ID: 17101176
[TBL] [Abstract][Full Text] [Related]
13. Eosinophil granule major basic protein regulates generation of classical and alternative-amplification pathway C3 convertases in vitro.
Weiler JM; Gleich GJ
J Immunol; 1988 Mar; 140(5):1605-10. PubMed ID: 3346544
[TBL] [Abstract][Full Text] [Related]
14. Evidence for different requirements in physical state for the interaction of lipopolysaccharides with the classical and alternative pathways of complement.
Wilson ME; Morrison DC
Eur J Biochem; 1982 Nov; 128(1):137-41. PubMed ID: 6756918
[TBL] [Abstract][Full Text] [Related]
15. Saliva of Rhipicephalus (Boophilus) microplus (Acari: Ixodidae) inhibits classical and alternative complement pathways.
Silva NC; Vale VF; Franco PF; Gontijo NF; Valenzuela JG; Pereira MH; Sant'Anna MR; Rodrigues DS; Lima WS; Fux B; Araujo RN
Parasit Vectors; 2016 Aug; 9(1):445. PubMed ID: 27515662
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
Kievits F; Kijlstra A
Immunology; 1985 Mar; 54(3):449-56. PubMed ID: 3844370
[TBL] [Abstract][Full Text] [Related]
17. [Formation of classical C3 convertase during the alternative pathway of human complement activation].
Kozlov LV; Shibanova ED; Zinchenko AA
Biokhimiia; 1987 Apr; 52(4):660-6. PubMed ID: 3647798
[TBL] [Abstract][Full Text] [Related]
18. A component of the medicinal herb ephedra blocks activation in the classical and alternative pathways of complement.
Ling M; Piddlesden SJ; Morgan BP
Clin Exp Immunol; 1995 Dec; 102(3):582-8. PubMed ID: 8536376
[TBL] [Abstract][Full Text] [Related]
19. The role of carrageenan in complement activation.
Baker KC; Nicklin S; Miller K
Food Chem Toxicol; 1986 Sep; 24(9):891-5. PubMed ID: 3096850
[TBL] [Abstract][Full Text] [Related]
20. Oxiagin from the Naja oxiana cobra venom is the first reprolysin inhibiting the classical pathway of complement.
Shoibonov BB; Osipov AV; Kryukova EV; Zinchenko AA; Lakhtin VM; Tsetlin VI; Utkin YN
Mol Immunol; 2005 Jun; 42(10):1141-53. PubMed ID: 15829304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
